News
NLSPW
--
0.00%
--
BRIEF-NLS Pharmaceutics Announces Preclinical Data Demonstrating The Potential Of NLS-4 (Lauflumide) To Treat Chronic Fatigue Associated With Long-Covid
reuters.com · 10/14 12:41
NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID
STANS, SWITZERLAND / ACCESSWIRE / October 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with r...
ACCESSWIRE · 10/14 12:30
36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021
RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5th \- 8th, 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor a...
ACCESSWIRE · 10/04 20:30
From BZ's Small Cap Healthcare Conference: Ocuphire Pharma Founder & CEO, Mina Sooch Begin Presenting
Click To Tune In Here: https://www.youtube.com/watch?v=KS30Mcu5ei8
Click To Tune In Here:  · 09/29 13:52
BRIEF-NLS Pharmaceutics Announces $20 Mln Standby Equity Distribution Agreement
reuters.com · 09/28 12:46
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment
STANS, SWITZERLAND / ACCESSWIRE / September 28, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with...
ACCESSWIRE · 09/28 12:30
NLS Pharmaceutics to Participate in the Benzinga Healthcare Small Cap Conference
STANS, SWITZERLAND / ACCESSWIRE / September 24, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients ...
ACCESSWIRE · 09/24 12:15
NLS Initiates Phase 2 Trial for Quilience in Narcolepsy and Announces First Patient Enrolled
STANS, SWITZERLAND / ACCESSWIRE / September 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients ...
ACCESSWIRE · 09/14 12:30
NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference
STANS, SWITZERLAND / ACCESSWIRE / September 8, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients w...
ACCESSWIRE · 09/08 12:00
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Application Covering its Proprietary Mazindol Formulation
STANS, SWITZERLAND / ACCESSWIRE / August 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients wit...
ACCESSWIRE · 08/19 11:52
NLS Pharmaceutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
STANS, SWITZERLAND / ACCESSWIRE / August 5, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare a...
ACCESSWIRE · 08/05 12:30
NLS Pharmaceutics Announces the Appointment of Eric Konofal, M.D., Ph.D. as Chief Scientific Officer
STANS, SWITZERLAND / ACCESSWIRE / July 19, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central ...
ACCESSWIRE · 07/19 12:30
NLS Pharmaceutics Announces FDA Acceptance of IND Application to Initiate Clinical Trials with Quilience(R) (mazindol ER) to Treat Narcolepsy
Planned Phase 2a clinical trial anticipated to commence in August 2021
ACCESSWIRE · 07/15 12:15
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th \- 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the thre...
ACCESSWIRE · 07/08 15:20
BRIEF-NLS Pharmaceutics Announces New Study Data Confirming Mazindol's Unique Orexin Pathway Activation For Treating Narcolepsy
reuters.com · 05/18 12:24
BRIEF-NLS Pharmaceutics Announces Patent Issuance In Europe
reuters.com · 05/05 12:42
BRIEF-NLS Pharmaceutics Announces Issuance of Canadian Patent Covering Formulation Mazindol CR
reuters.com · 03/29 12:56
BRIEF-NLS Pharmaceutics Obtains License To Full Regulatory Data For Sanorex
reuters.com · 03/12 13:06
Webull provides a variety of real-time NLSPW stock news. You can receive the latest news about NLS PHARMACEUTIC through multiple platforms. This information may help you make smarter investment decisions.
About NLSPW
NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.